Atezolizumab/bevacizumab/lenvatinibImmune‑related hypopituitarism, primary hypothyroidism and no response: 3 case reports

被引：0

作者：

机构：

来源：

Reactions Weekly | 2023年 / 1961卷 / 1期

关键词：

D O I：

10.1007/s40278-023-41333-x

中图分类号：

学科分类号：

摘要：

引用

下载

页码：76 / 76

共 50 条

[1] Atezolizumab/nivolumabOvert hypothyroidism and subclinical hypothyroidism: 3 case reports
Reactions Weekly, 2022, 1934 (1) : 89 - 89
[2] Atezolizumab/bevacizumab/lenvatinibThyroid dysfunction in the form of hypothyroidism and lack of efficacy: 4 case reports
Reactions Weekly, 2023, 1981 (1) : 69 - 69
[3] Atezolizumab/Bevacizumab/NivolumabLack of efficacy: 2 case reports
Reactions Weekly, 2025, 2040 (1) : 129 - 129
[4] Atezolizumab/bevacizumab/lenvatinibLack of efficacy: 5 case reports
Reactions Weekly, 2023, 1963 (1) : 98 - 98
[5] Atezolizumab/avelumabHypothyroidism, worsening of hypothyroidism and thyrotoxicosis: 23 case reports
Reactions Weekly, 2021, 1876 (1) : 62 - 62
[6] Three cases of immune-related hypopituitarism after atezolizumab–bevacizumab treatment for hepatocellular carcinoma
Nozomi Furuichi
Atsushi Naganuma
Takuya Kaburagi
Yuhei Suzuki
Takashi Hoshino
Nobuyuki Shibusawa
Suguru Horiguchi
Takeshi Hatanaka
Satoru Kakizaki
Toshio Uraoka
Clinical Journal of Gastroenterology, 2023, 16 : 422 - 431
[7] A case of profound primary hypothyroidism in childhood causing a secondary hypopituitarism
Hamill, C. F.
Mullan, K.
IRISH JOURNAL OF MEDICAL SCIENCE, 2018, 187 : S204 - S204
[8] Fibrolamellar hepatocellular carcinoma treated with atezolizumab and bevacizumab: two case reports
Al Zahrani, Ali
Alfakeeh, Ali
JOURNAL OF MEDICAL CASE REPORTS, 2021, 15 (01)
[9] Atezolizumab/ipilimumabMyocarditis: 3 case reports
Reactions Weekly, 2023, 1986 (1) : 76 - 76
[10] Fibrolamellar hepatocellular carcinoma treated with atezolizumab and bevacizumab: two case reports
Ali AL Zahrani
Ali Alfakeeh
Journal of Medical Case Reports, 15

← 1 2 3 4 5 →